Lysipressin

Peptide design stands as a crucial factor in advancing NRT effectiveness for smoking cessation treatment. Clinical evidence demonstrates significant improvements through optimized peptide structures, enhanced delivery systems, and personalized approaches. These advancements address traditional limitations while offering promising solutions for improved bioavailability and patient compliance. Contact us for customized formulation of NRT-Peptide combination for your research.

Lysipressin Acetate CAS: 50-57-7

Name:Lysipressin Acetate

Type: Pharmaceutical Peptide

CAS:50-57-7

Purity:98%

Appearance:White powder

Packing Specification:1g, 10g, 100g

Storage:-20 ℃

Molecular Formula:C₄₆H₆₅N₁₃O₁₂S₂

Molecular Weight:1056.22